Comparative investigation of Platelet-rich plasma injection with corticosteroid and local anesthetic in osteoarthritis patients

Comparative study of intra-knee injection of leukosit-poor platelet-rich plasma compared to corticosteroids and local anesthetic in patients with second and third degree osteoarthritis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211017052786N5

Enrollment

Registered

2023-01-30

Start date

2023-03-16

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

2nd and 3rd degree of knee osteoarthritis. Osteoarthritis of knee

Interventions

Intervention 1: Intervention group 1 : Patients in group one (platelet-rich plasma (PRP)) randomly receive one intra-articular injection of autologous PRP with low leukocyte. The kit used is PRP Kit s

Eligibility

Sex/Gender

All

Age

55 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient over 55 years old History of chronic pain, swelling or reduced range of motion in the knee joint Clinical and radiological confirmation of the knee (Kolgren-Lawrence grade II-III) by X-ray images in anteroposterior and lateral projections.

Exclusion criteria

Exclusion criteria: Post-traumatic knee osteoarthritis Cancerous diseases Endocrine diseases (gout, diabetes) Autoimmune diseases (rheumatoid arthritis) Acute and chronic infectious disorders Blood coagulation disorders (thrombocytopenia, coagulopathy) Previous interventions on the knee joint (i.e. puncture, block, arthroscopy) Hormonal therapy or non-steroidal anti-inflammatory drugs (NSAIDs) (within 10 days) before the intervention

Design outcomes

Primary

Measure	Time frame
Pain reduction rate in patients. Timepoint: 3 months after injection. Method of measurement: Visual analog scale (VAS).;The rate of reduction of acute pain in patients. Timepoint: Immediately after injection and then once a month for up to 6 months. Method of measurement: Visual analog scale (VAS).;The rate of reduction of chronic pain in patients. Timepoint: 6 months after injection. Method of measurement: Visual analog scale (VAS).;Satisfaction rate of patients regarding the reduction of pain after injection. Timepoint: Immediately after injection and then once a month for up to 6 months. Method of measurement: In the form of scoring from 0 to 10, the closer we get to 10, the more satisfaction is achieved.	—

Measure

Time frame

Pain reduction rate in patients. Timepoint: 3 months after injection. Method of measurement: Visual analog scale (VAS).;The rate of reduction of acute pain in patients. Timepoint: Immediately after injection and then once a month for up to 6 months. Method of measurement: Visual analog scale (VAS).;The rate of reduction of chronic pain in patients. Timepoint: 6 months after injection. Method of measurement: Visual analog scale (VAS).;Satisfaction rate of patients regarding the reduction of pain after injection. Timepoint: Immediately after injection and then once a month for up to 6 months. Method of measurement: In the form of scoring from 0 to 10, the closer we get to 10, the more satisfaction is achieved.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Ahmadi

Tehran University of Medical Sciences

abbasahmadi27@yahoo.com+98 25 3885 6440

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026